contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.

MFN – 5 May 25              Mendus AB (publ): Mendus strengthens late-stage clinical developmen...    Mendus AB ('Mendus' publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the appointment of Tariq Mughal, MD FRCP FRCPath, as Chief Me...                             Højt profileret rekruttering som CMO. Aktien +22%

Inderes ophører med dækningen af Mendus, da selskabet har opsagt analyseaftalen. Mendus fokuserer på AML-behandlinger og sigter mod fase III-fasen inden 2025. Den første kommercialisering forventes i 2029. De største risici er relateret til sikring af finansiering og kliniske resultater.                   Inderes              Mendus: We are discontinuing coverage - Inderes    We are discontinuing our coverage of Mendus as the company has terminated the equity research agreement. Consequently, we will no longer be giving a target price (was SEK 14) or a recommendation (was Accumulate) for the stock.

Mendus påbegyndte planlægningen af et nyt klinisk studie med ilixadencel mod bløddelssarkom og gjorde fremskridt med patientrekrutteringen til CADENCE-studiet. Takket være omkostningsbesparelser rækker likviditetsreserven nu frem til Q4’25 (tidligere Q3’25). Nedenfor er en dugfrisk selskabsrapport om Mendus skrevet af Antti.                    Inderes              Mendus Q3'24: Building basis for a pivotal trial - Inderes    In Q3, Mendus reported bringing ilixadencel back into clinical development, opening research centers for the CADENCE trial and progressing in building Phase III readiness.                             I 3. kvartal rapporterede Mendus, at de har genoptaget den kliniske udvikling af ilixadencel, åbnet forskningscentre for CADENCE-studiet og gjort fremskridt med at opbygge fase III-parathed. Driftsomkostningerne for kvartalet lå under vores forventninger på grund af implementerede omkostningsbesparelser, som bør fortsætte i de kommende måneder. Som følge heraf er selskabets cash runway blevet forlænget til Q4’25 (var Q3’25). Vi fastholder vores kursmål på 14 SEK og sænker vores anbefaling til Akkumuler (var Køb) på grund af aktiekursstigningen i forhold til vores DCF-model og nordiske immunonkologiske peers.

Pareto har givet en købsanbefaling med et kursmål på 14 kroner:                  Affärsvärlden              Mendus stiger efter köp från Pareto | Affärsvärlden                              Kurs +26,88%

Her er Anttis selskabsrapport efter Mendus’ Q2.  For Mendus markerede Q2’24 starten på det pivotale CADENCE-studie i akut myeloid leukæmi (AML). Selskabet annoncerede også planer om at genstarte den kliniske udvikling af ilixadencel i bløddelssarkomer (STS). Sideløbende opbygger Mendus parathed til et pivotalt studie i AML inden 2. halvår 2025. Disse vigtige udviklinger understøttes af en sikret cash runway frem til 3. kvartal 2025. Vi inkluderer STS-indikationen i vores estimater og opjusterer vores estimater for R&D-omkostninger for de kommende år. Vi fastholder vores anbefaling (Køb) samt vores kursmål på 14 SEK, da både vores DCF-model og peer-værdiansættelse tyder på en upside for aktien.  https://www.inderes.fi/research/mendus-q224-ilixadencel-to-return-to-the-clinical-arena

Mendus offentliggjorde sin rapport for andet kvartal fredag den 23.8. I et interview med Antti opsummerer administrerende direktør Erik Manting, hvad der skete i andet kvartal, fortæller om de vigtigste resultater i CADENCE-studiet og beretter om det nye studie med lægemidlet Ilixadencel.                   Inderes              Mendus Q2´24: The CADENCE trial has started - Inderes    Time: 23.08.2024 klo 15.42 Mendus released their Q2 report today 23/8 and in this interview, you can listen to CEO Erik Manting summarize the second quarter. What has happened during Q2, main milestones in CADENCE and the new communicated trial with...                             Emner: 00:00 Start  00:14 Hvad der er sket i løbet af 2. kvartal  04:58 CADENCE-studiet  08:04 Vigtigste milepæle i CADENCE  09:36 Immunaktivering hos AML-patienter – Hvad har I lært?  12:19 Nyt studie med Ilixadencel  15:16 Tidslinje for studiet  15:54 Opbygning af parathed inden for AML

Mendus

Mendus has announced the launch of its chronic myeloid leukaemia (CML) programme for lead immunotherapy candidate, vididencel. Preparations have been completed and regulatory clearance has been...

Mendus has announced the launch of its chronic myeloid leukaemia (CML) programme for lead immunotherapy candidate, vididencel. Preparations have been completed and regulatory clearance has been received for the Phase I VITAL-CML study, which will assess the safety and feasibility of vididencel in CML patients with suboptimal responses to tyrosine kinase inhibitors (TKIs), the standard of care for the disease. VITAL-CML has been designed to recruit c 24 participants, and an initial top-line readout based on the first eight patients is anticipated in H226, which we believe could represent an important inflection point. If successful, Mendus plans to proceed with a subsequent Phase IIa trial (called VITAL-TFR2). While the primary focus for vididencel is in acute myeloid leukaemia (AML), in our view, the expansion into CML is promising and has the potential to significantly broaden its application, which may translate to a sizeable commercial opportunity.

Mendus: CML programme commences - Edison

Mendus: CML programme commences - Edison